Last updated: August 4, 2026
LEXETTE is a branded topical corticosteroid containing halobetasol propionate 0.05% in an aerosol foam. Mayne Pharma commercializes the product in the United States for short-term treatment of mild-to-moderate plaque psoriasis in patients aged 12 years and older. Its commercial value depends on the premium for foam delivery, payer access, dermatology prescribing, and the timing of generic competition. Public filings do not provide a standalone LEXETTE revenue series, so product-level sales and profitability cannot be stated reliably. [1][2]
What is LEXETTE and how is it positioned?
LEXETTE is a high-potency topical corticosteroid delivered as a foam rather than a cream, ointment, lotion, or solution. The FDA approved LEXETTE in 2018 under NDA 209489. The labeled indication is topical treatment of mild-to-moderate plaque psoriasis of the scalp and body in patients 12 years and older. Treatment is limited to two weeks, consistent with the safety profile of super-high-potency topical corticosteroids. [1]
LEXETTE product profile
| Attribute |
LEXETTE |
| Active ingredient |
Halobetasol propionate |
| Strength |
0.05% |
| Dosage form |
Topical aerosol foam |
| FDA application |
NDA 209489 |
| Indication |
Mild-to-moderate plaque psoriasis |
| Approved population |
Adults and pediatric patients aged 12 years and older |
| Treatment duration |
Up to two weeks |
| Commercial sponsor |
Mayne Pharma |
| Primary market |
United States dermatology |
The foam vehicle is the main commercial differentiator. It can be easier to spread across hair-bearing areas and large plaque surfaces than an ointment. The differentiation is practical rather than pharmacological: halobetasol is an established corticosteroid, and the product does not have a novel systemic mechanism or biologic profile.
How large is the market for LEXETTE?
LEXETTE competes in the prescription topical psoriasis market, which is fragmented across corticosteroids, vitamin D analogues, retinoids, combination products, nonsteroidal agents, and newer topical therapies. The relevant addressable segment is narrower than the overall psoriasis market because LEXETTE is intended for limited-duration use and is not a systemic therapy.
Main competitive groups
| Competitive group |
Examples |
Competitive effect on LEXETTE |
| Generic halobetasol |
Cream, ointment, lotion and other topical forms |
Creates price pressure and substitution risk |
| Branded halobetasol |
Bryhali lotion, Ultravate-related products |
Competes on vehicle, dosing and payer positioning |
| High-potency topical steroids |
Clobetasol foams, creams, gels and solutions |
Limits differentiation based solely on potency |
| Nonsteroidal topicals |
ZORYVE, VTAMA, tacrolimus and pimecrolimus products |
Compete on chronic-use suitability and safety positioning |
| Combination products |
Calcipotriene and corticosteroid combinations |
Compete on efficacy convenience |
| Systemic and biologic psoriasis therapies |
IL-17, IL-23 and TNF inhibitors |
Reduce the strategic importance of topical therapy in moderate-to-severe disease |
LEXETTE has a stronger commercial rationale in scalp psoriasis and patients who resist ointments. Its position is weaker when payers treat it as therapeutically interchangeable with lower-cost generic corticosteroids.
What is the financial trajectory of LEXETTE?
Mayne Pharma reports commercial performance primarily by business segment and geographic region rather than by individual brand. Public company filings do not establish a verified, product-level LEXETTE revenue history. The financial trajectory therefore must be assessed through launch timing, portfolio strategy, market access and the structure of the topical dermatology market. [2]
Commercial development phases
| Period |
Market event |
Financial implication |
| 2018 |
FDA approval |
Established regulatory entry and began the pre-launch investment period |
| 2019 onward |
U.S. commercial availability |
Shifted the product from development expense to promotional and selling expense |
| 2020-2022 |
Expansion within Mayne’s U.S. dermatology portfolio |
Increased cross-selling potential through dermatology prescriber relationships |
| 2023 onward |
Mature branded topical phase |
Growth became dependent on refill persistence, payer coverage and promotional efficiency |
| Generic-entry period |
Timing depends on ANDA approvals and enforceable patent protection |
Could produce rapid price and volume disruption |
LEXETTE is unlikely to be a material standalone driver of Mayne Pharma’s consolidated revenue compared with the company’s broader portfolio. Its value is more likely to come from recurring dermatology prescriptions, portfolio density and contribution margin than from blockbuster-scale sales.
Revenue drivers
The principal revenue drivers are:
- Prescription volume among dermatologists and advanced practice providers.
- Net price after rebates, commercial discounts and patient-support programs.
- Access under commercial and government formularies.
- Use in scalp and body psoriasis where foam application offers a practical advantage.
- Persistence of prescribing after promotional support declines.
- The absence or presence of an AB-rated generic equivalent.
The key financial risk is that gross prescription growth may not translate into net sales growth. Topical dermatology brands often rely on copay support and payer concessions, particularly when the active ingredient is available in older generic dosage forms.
When does LEXETTE lose exclusivity?
LEXETTE’s regulatory exclusivity and patent exclusivity are separate issues. The active ingredient, halobetasol propionate, predates LEXETTE by decades and does not provide meaningful composition-of-matter protection for the product.
Regulatory exclusivity
LEXETTE was approved in 2018 as a new dosage form of an established active ingredient. It was not a conventional new chemical entity with a five-year NCE exclusivity period. Any short-duration FDA exclusivity associated with the approval would not be the principal barrier to generic entry today.
The practical protection is therefore expected to depend on listed patents, formulation claims, manufacturing claims and the ability of an ANDA applicant to certify around those rights.
Patent expiration
The relevant patent question is not whether halobetasol itself is old. It is whether a generic applicant can reproduce the foam formulation without infringing enforceable formulation, container, propellant, manufacturing or use patents.
The FDA Orange Book should be used to identify current patents associated with NDA 209489 and their listed expiration dates. [3] A patent listed for a topical foam can delay approval after a Paragraph IV notice, but it does not guarantee long-term commercial exclusivity. A patent challenge can trigger litigation, while a successful invalidity or noninfringement position can allow approval before the listed patent expiry.
What patents protect LEXETTE?
The protection strategy for LEXETTE is formulation-led rather than molecule-led. The likely claim categories include:
Foam formulation patents
These claims can cover the composition of the foam, the relationship among the active ingredient, solvent, surfactant and propellant, and the physical characteristics needed for topical delivery.
Container and dispensing patents
Aerosol products may rely on claims covering the canister, valve, actuator or delivery system. These rights can be commercially relevant even when the underlying composition is old.
Manufacturing patents
Manufacturing claims can address mixing, filling, stability control and production conditions. They are harder for a generic manufacturer to avoid if the branded process produces a specific foam performance profile, but they are also vulnerable if the claims are narrow.
Method-of-use patents
Use claims may cover treatment of plaque psoriasis, scalp psoriasis or a particular dosing regimen. Their commercial value depends on the scope of the label and whether an ANDA applicant can use a skinny label that omits the protected method.
Method-of-use rights are less powerful for LEXETTE than they would be for a drug with a new disease indication because topical corticosteroid use is already well established.
Are there Paragraph IV challenges to LEXETTE?
A Paragraph IV challenge would be the principal U.S. route for an ANDA applicant seeking approval before expiration of an Orange Book-listed patent. The applicant would assert that the patent is invalid, unenforceable or not infringed.
A meaningful generic challenge would likely focus on:
- Obviousness of the foam formulation.
- Lack of adequate written description or enablement.
- Narrow claim construction.
- Design-around opportunities involving propellant or excipient selection.
- Noninfringement based on a different container or manufacturing process.
- Whether the listed patent properly claims the approved product.
The commercial significance of a Paragraph IV case depends on the first filer’s ability to secure 180-day exclusivity, the number of subsequent ANDA filers and the expected settlement date. Public information does not establish a definitive, current Paragraph IV settlement or a confirmed generic launch date for LEXETTE. The FDA Orange Book and federal court docket records remain the controlling sources for current status. [3][4]
What is the FDA and Orange Book status of LEXETTE?
LEXETTE has FDA approval as a prescription topical aerosol foam under NDA 209489. The product is not a biologic, so biosimilar pathways do not apply. Generic competition would proceed through the ANDA pathway rather than the abbreviated biosimilar pathway. [1][3]
Regulatory risk profile
| Issue |
Assessment |
| FDA approval |
Established |
| NCE protection |
Not the central source of current exclusivity |
| Dosage-form differentiation |
Important commercial feature |
| Orange Book exposure |
Central to generic timing |
| Biosimilar risk |
Not applicable |
| ANDA risk |
High over the long term because halobetasol is an established active ingredient |
| Labeling risk |
Limited unless FDA requires safety or use revisions |
| Manufacturing complexity |
Moderate because aerosol foam performance must be reproduced |
How strong is the LEXETTE patent estate?
LEXETTE’s patent estate is commercially useful but structurally vulnerable compared with a new chemical entity or biologic. The active ingredient is old, and competing halobetasol products demonstrate that the therapeutic class is established. The defensible asset is the specific foam delivery system.
Patent-strength assessment
| Protection layer |
Relative strength |
Reason |
| Active ingredient |
Weak |
Halobetasol propionate is long established |
| Foam formulation |
Moderate |
Can create meaningful barriers if claims are technically specific |
| Aerosol delivery system |
Moderate |
May complicate substitution but can be designed around |
| Manufacturing process |
Variable |
Stronger if process is essential and difficult to reproduce |
| Method of use |
Weak to moderate |
Psoriasis use is established and may support skinny-label strategies |
| Regulatory exclusivity |
Low at present |
Approval occurred in 2018 |
| Brand and prescriber familiarity |
Moderate |
Supports retention but does not block generic substitution |
The estate can protect the branded presentation through the period when the foam commands a price premium, but it is unlikely to prevent eventual erosion if an ANDA applicant develops a substitutable aerosol foam.
What generic entry risks exist for LEXETTE?
Generic entry would affect LEXETTE through both price and formulary mechanics. An AB-rated generic could be substituted at the pharmacy level, depending on state law and payer rules. Even a therapeutically similar non-AB product could pressure formulary placement and reduce branded net pricing.
Likely launch scenarios
First generic launch. The first approved generic could capture a disproportionate share of prescriptions if it receives favorable formulary treatment and secures 180-day exclusivity.
Authorized generic or license-based entry. Mayne or a commercial partner could use an authorized generic strategy to retain part of the market economics while limiting the first challenger’s price advantage.
At-risk launch. A generic applicant could launch before patent litigation is resolved. This would create substantial damages exposure if the patent is later upheld and infringed.
Delayed entry. A settlement could postpone launch until an agreed date while preserving some remaining branded revenue.
The most exposed segment is price-sensitive maintenance use. The least exposed segment is patients and prescribers who value foam application for the scalp or who have established product-specific tolerability.
What licensing deals affect LEXETTE?
Mayne Pharma’s commercial strategy has included branded dermatology products and acquired or in-licensed assets. LEXETTE should be analyzed within that portfolio rather than as an isolated discovery asset. Public reporting does not establish a current, separately disclosed LEXETTE royalty stream or a material third-party licensing obligation that can be quantified from company filings. [2]
For valuation, the relevant contractual questions are:
- Whether Mayne owns or licenses U.S. commercial rights.
- Whether royalties are paid on net sales.
- Whether milestone obligations remain.
- Whether manufacturing is internal or outsourced.
- Whether a generic settlement would require a license or supply arrangement.
- Whether rights are limited geographically to the United States.
How does LEXETTE compare with generic halobetasol?
| Factor |
LEXETTE |
Generic halobetasol |
| Active ingredient |
Halobetasol propionate 0.05% |
Usually the same |
| Vehicle |
Aerosol foam |
Depends on dosage form |
| Price |
Branded premium |
Lower |
| Patient convenience |
Strong for scalp and hair-bearing areas |
Product-dependent |
| Payer leverage |
Vulnerable without preferred formulary placement |
Usually stronger on cost |
| Substitution |
Depends on dosage form and AB rating |
Depends on FDA rating |
| Patent exposure |
Formulation and delivery claims |
Challenges listed patents |
| Long-term margin |
Dependent on differentiation |
Typically compressed after entry |
LEXETTE’s commercial defense is not potency. It is delivery convenience, product familiarity, physician preference and patient persistence.
What is the investment outlook for LEXETTE?
LEXETTE is a mature branded dermatology asset with moderate residual value and high long-term erosion risk. Its upside depends on efficient promotion and stable payer access, not on expansion into a large new indication.
The strongest value case includes:
- Continued prescriber adoption in scalp psoriasis.
- Limited near-term generic competition.
- Stable net pricing.
- Low manufacturing cost.
- Cross-selling through Mayne’s dermatology portfolio.
- A patent or settlement timetable that delays direct substitution.
The downside case includes:
- An AB-rated aerosol generic.
- Payer exclusion or higher patient copays.
- Rebates that reduce net price.
- Weak refill persistence after the initial treatment course.
- Patent invalidation or noninfringement.
- Competition from nonsteroidal topicals that are more suitable for repeated use.
LEXETTE should be valued as a cash-generating specialty topical with patent-event risk, not as a platform asset or biologic franchise.
Key Takeaways
- LEXETTE is halobetasol propionate 0.05% aerosol foam, approved by the FDA in 2018 under NDA 209489.
- Mayne Pharma does not publicly disclose a verified standalone LEXETTE revenue series.
- The product’s commercial differentiation is the foam vehicle, especially for scalp and hair-bearing areas.
- Halobetasol’s age weakens molecule-level protection; formulation, delivery and manufacturing patents carry the main defensive burden.
- Biosimilar risk does not apply. The relevant threat is an ANDA-based generic.
- A Paragraph IV challenge could accelerate generic entry if listed patents are invalidated or avoided.
- The product’s financial trajectory depends on net pricing, payer access, refill behavior and the timing of an AB-rated generic.
- LEXETTE has moderate formulation protection but weaker long-term exclusivity than a new chemical entity or biologic.
FAQs
Is LEXETTE a steroid or a biologic?
LEXETTE is a super-high-potency topical corticosteroid. It is a small-molecule drug and is not a biologic.
Can patients use LEXETTE indefinitely?
No. The FDA label limits treatment to short-term use, generally up to two weeks, because prolonged exposure to high-potency topical corticosteroids increases the risk of local and systemic adverse effects. [1]
Is generic halobetasol foam available?
Availability depends on FDA approval, Orange Book status, patent certifications and commercial launch. Generic halobetasol products in other dosage forms do not automatically establish availability of an equivalent aerosol foam.
What would an AB-rated generic do to LEXETTE sales?
An AB-rated generic could enable pharmacy substitution and create rapid price and volume pressure. The effect would depend on state substitution rules, payer contracts, product availability and whether the generic matches the same dosage form.
Does LEXETTE compete with biologic psoriasis drugs?
Yes, indirectly. Biologics target moderate-to-severe psoriasis and can reduce topical treatment demand in some patients. LEXETTE remains focused on localized or less extensive disease where a topical product is appropriate.
References
- U.S. Food and Drug Administration. (2018). LEXETTE (halobetasol propionate) aerosol, foam: Prescribing information.
- Mayne Pharma Group Limited. (2023). Annual report 2023.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). ANDA and patent certification resources.
